SLS
SELLAS Life Sciences Group, Inc.
1.46
-
0.06
3.95%
8 x 1.44
8 x 1.47
bid
ask
8 @ 04:00 PM
1.46+0.00 (0.00%)
Bearish
29
Bullish
115
sentiment
1.42
day range
1.54
0.51
52 week range
1.83
Prev Close1.52
Open1.53
Low1.42
High1.54
Volume1.28M
Avg. Volume1.47M
Market Cap82.15M
Inst. Own10.32%
Beta2.37
Short Ratio2.84
Div & Yield0.00 /
EPS-1.34
P/E0.00
1yr Target6.83
50day MA1.19
200day MA1.18
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | 0 | N/A | N/A | N/A |
2024-03-28 | 2023-12 | 0 | -0.25 | N/A | N/A |
2023-11-09 | 2023-09 | 0 | -0.33 | N/A | N/A |
2023-08-10 | 2023-06 | 0 | -0.31 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -0.47 | N/A | N/A |
2023-03-16 | 2022-12 | 0 | -0.43 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-11-14 | Alliance Global Partners | Upgrade | Buy | |
2022-06-27 | Cantor Fitzgerald | Upgrade | Overweight | |
2021-07-20 | Cantor Fitzgerald | Upgrade | Overweight | |
2019-11-14 | Maxim Group | Upgrade | Hold | Buy |
2019-04-07 | Alliance Global Partners | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-21 | BURNS JOHN THOMAS | Chief Financial Officer | 101.93K | Stock Award(Grant) |
2024-01-21 | FRANCOMANO ROBERT | Officer | 40.92K | Stock Award(Grant) |
2024-01-21 | KALIN KATHERINE BACH | Director | 8.50K | Stock Award(Grant) |
2017-12-28 | LOPEZ FABIO | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-01-21 | SCHEINBERG DAVID A | Director | 10.58K | Stock Award(Grant) |
2024-01-21 | STERGIOU ANGELOS M | Chief Executive Officer | 376.42K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Alyeska Investment Group, L.p. | 1.25M | 1.96M | 4.41% |
2023-06-29 | Vanguard Group Inc | 946.71K | 1.49M | 3.34% |
2023-06-29 | Blackrock Inc. | 283.37K | 444.89K | 1.00% |
2023-06-29 | Geode Capital Management, LLC | 188.07K | 295.26K | 0.66% |
2023-06-29 | Equitable Holdings, Inc. | 135.00K | 211.95K | 0.48% |
2023-06-29 | State Street Corporation | 97.13K | 152.49K | 0.34% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 592.27K | 929.87K | 2.09% |
2023-06-29 | Vanguard Extended Market Index Fund | 318.24K | 499.64K | 1.12% |
2023-05-30 | Fidelity Extended Market Index Fund | 101.70K | 174.42K | 0.36% |
2023-08-30 | iShares Micro Cap ETF | 63.00K | 92.61K | 0.22% |
2023-05-30 | Fidelity Total Market Index Fund | 36.80K | 63.11K | 0.13% |
2023-05-30 | Fidelity Series Total Market Index Fund | 25.07K | 43.00K | 0.09% |
Dividend
...
Dividend | Date |
---|---|
0.42 | 2010-12-09 |
0.15 | 2010-09-09 |
Split
...
Split | Date |
---|---|
1 : 50 | 2019-11-08 |
1 : 50 | 2019-11-06 |
1 : 30 | 2018-01-02 |
1 : 30 | 2018-01-01 |
1 : 20 | 2016-11-14 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
It’s probably Citadel jerking around and getting in there last licks before the Giv. Requires them to report in real-time. They love attacking small biotech
-
With a market cap of 50 mil and the low float they have a shit ton of room to do offering. It’s a 1 trick pony but the data is strong and they are sailing into the final stretch.
-
I sat she hits 4.00 in June from my ASCO experience
-
-
-
-
-
-
-
$SLS CHECK OUT $LGVN BEST DISCOUNT IN THE MARKET RIGHT NOW. Will be EASILY $75 by EOW… and if it wasn’t for the holiday last week it would be TRIP digits by the EOW….. Do you’re own DD. Don’t listen to paid bashers or fake bulls. Lot of them on these boards.
-
$SLS .88 is not accurate
-
Closing Bell: Solaris Resources Inc down on Friday (SLS)
news.google.com • -
Closing Bell: Solaris Resources Inc up on Wednesday (SLS)
news.google.com • -
Closing Bell: Solaris Resources Inc down on Monday (SLS)
news.google.com • -
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
seekingalpha.com • -
Why Is Sellas Life Sciences (SLS) Stock Down 25% Today?
investorplace.com • -
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
globenewswire.com • -
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
investorplace.com • -
SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
globenewswire.com • -
SELLAS Life Sciences Announces Settlement of Derivative Litigation
globenewswire.com • -
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
globenewswire.com • -
What's Up With Sellas Life Sciences Stock Today?
benzinga.com • -
SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
globenewswire.com • -
Sellas: Late-Stage Biotech Approaches 2023 Approval With Solid Funding
seekingalpha.com • -
SLS Stock: 8 Things to Know About SELLAS Life Sciences as It Enjoys Reddit Bump
investorplace.com • -
Shares of Startup Biotechs Soar on Cancer Study Results
gurufocus.com • -
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
globenewswire.com •